It would be of interest to explore the outcomes in patients with bone metastases and evaluate whether there is a relation between bone metastases related outcomes and RANKL expression (tumor or serum) as well as RANKL/OPG ratio (2). The gene discussed is TNFRSF11B; the disease is neoplasm.